Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Asset Writedowns and Impairment (2020 - 2021)

Karyopharm Therapeutics (KPTI) has disclosed Asset Writedowns and Impairment for 2 consecutive years, with -$114000.0 as the latest value for Q3 2021.

  • For the quarter ending Q3 2021, Asset Writedowns and Impairment changed N/A year-over-year to -$114000.0, compared with a TTM value of $86000.0 through Mar 2022, down 79.08%, and an annual FY2020 reading of $329000.0, changed N/A over the prior year.
  • Asset Writedowns and Impairment was -$114000.0 for Q3 2021 at Karyopharm Therapeutics, down from $118000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $329000.0 in Q4 2020 and bottomed at -$114000.0 in Q3 2021.